PD‐1 and PD‐L1 upregulation promotes CD8+ T‐cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients

No abstract is available for this paper.

• Publication year

  2011

• Venue

  International Journal of Cancer

• Publication date

  2011-02-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ijc.25397PMID 20473887
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1

  2009cited by this paper
• Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma

  2009cited by this paper
• Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters.

  2009cited by this paper
• Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma.

  2009cited by this paper
• Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

  2009cited by this paper
• The Common γ-Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands

  2008cited by this paper
• PD-1 and its ligands in tolerance and immunity.

  2008cited by this paper
• Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis.

  2008cited by this paper
• Inhibitory B7-family molecules in the tumour microenvironment

  2008cited by this paper
• Implications of B7-H1 Expression in Clear Cell Carcinoma of the Kidney for Prognostication and Therapy

  2007cited by this paper
• The B7 Family and Cancer Therapy: Costimulation and Coinhibition

  2007cited by this paper
• PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors.

  2007cited by this paper
• Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients.

  2007cited by this paper
• PD‐L1 (B7‐H1) expression by urothelial carcinoma of the bladder and BCG‐induced granulomata

  2007cited by this paper
• 879: PD-L1 (B7-H1) Expression by Urothelial Carcinoma of the Bladder and BCG-Induced Granulomata: Associations with Localized Stage Progression

  2007cited by this paper
• Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

  2007cited by this paper
• The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection

  2007cited by this paper
• Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer

  2007cited by this paper
• PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma.

  2007cited by this paper
• Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion

  2007cited by this paper
• Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers

  2007cited by this paper
• PD-1 Is Expressed by Tumor-Infiltrating Immune Cells and Is Associated with Poor Outcome for Patients with Renal Cell Carcinoma

  2007cited by this paper
• Tissue expression of PD-L1 mediates peripheral T cell tolerance

  2006cited by this paper
• Circulating and Liver Resident CD4+CD25+ Regulatory T Cells Actively Influence the Antiviral Immune Response and Disease Progression in Patients with Hepatitis B1

  2006cited by this paper
• PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis.

  2006cited by this paper
• The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.

  2006cited by this paper
• Regulatory T cells, tumour immunity and immunotherapy

  2006cited by this paper
• PD-L1 is induced in hepatocytes by viral infection and by interferon-α and -γ and mediates T cell apoptosis

  2006cited by this paper
• Sustained low-level expression of interferon-γ promotes tumor development: potential insights in tumor prevention and tumor immunotherapy

  2005cited by this paper
• Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells.

  2005cited by this paper
• PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells

  2004cited by this paper
• PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells.

  2004cited by this paper
• PD-1 Inhibits Antiviral Immunity at the Effector Phase in the Liver

  2003cited by this paper
• B7-H1 pathway and its role in the evasion of tumor immunity

  2003cited by this paper
• Viral pathogenesis of hepatocellular carcinoma

  2002cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

  2000cited by this paper
• Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes.

  1996cited by this paper
• Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes.

  1996cited by this paper

• The role of immune checkpoint molecules in cancers

  2026cites this paper
• Hot and Cold HCC: Uncoupling Viral Oncogenesis and Therapy

  2025cites this paper
• Prospects for the application of pathological response rate in neoadjuvant therapy for gastric cancer

  2025cites this paper
• PD‐1/PD‐L1 in Hepatocellular Carcinoma (2014–2024): A Combined Macro and Micro Analysis of Immunotherapy Implications

  2025cites this paper
• Roles of anoikis in hepatocellular carcinoma: mechanisms and therapeutic potential

  2025cites this paper
• Improving surgical treatments for hepatocellular carcinoma

  2025cites this paper
• Immuno-Activated, Highly Expressing PD-1 Phenotype in Hepatocellular Carcinoma Is Associated with a Lower Recurrence Rate

  2025cites this paper
• Evaluation of PD-L1 and TIM-3 Pathways in T Cells During Experimental Bovine Leukemia Virus Infection in Sheep

  2025cites this paper
• Avidity‐Based Capture of PD‐L1‐Expressing Exosomes via Dendrimer–Peptide Conjugates: A Nanoengineered Platform for Enhanced Prediction of Immunotherapy Response

  2025cites this paper
• Therapeutic Synergy of Silibinin‐Loaded Nanogel and Low‐Dose Gamma Radiation in Hepatocellular Carcinoma: Emphasis on EMT, Angiogenesis, and Immune Response

  2025cites this paper
• Targeting immune microenvironment in cervical cancer: current research and advances

  2025cites this paper
• The Expression of Programmed Cell Death Ligand-1 and its Relationship with Infiltration, Metastasis and Prognosis in Cervical Squamous Cell Carcinoma

  2025cites this paper
• Combined radiation and immune checkpoint inhibitor therapy for metastatic or recurrent hepatocellular carcinoma: a real-world study of 108 patients

  2025cites this paper
• Advances in understanding ferroptosis mechanisms and their impact on immune cell regulation and tumour immunotherapy

  2025cites this paper
• Prognostic relevance of the neutrophil/lymphocyte ratio in diffuse large B-cell lymphoma: a systematic review and meta-analysis and dose–response evidence

  2025cites this paper
• Leveraging liquid biopsy to uncover resistance mechanisms and guide personalized immunotherapy

  2025cites this paper
• Clinical outcomes of transarterial chemoembolization combined with durvalumab for advanced and metastatic biliary tract cancer

  2025cites this paper
• Advances and challenges in molecular understanding, early detection, and targeted treatment of liver cancer

  2025cites this paper
• Distinct Roles of HHLA2 and PD-L1 in the Immune Cell and Prognosis of Hepatocellular Carcinoma

  2025cites this paper
• Advancements in second-line treatment research for hepatocellular carcinoma

  2024cites this paper
• Transarterial Embolization Enhances Programmed Cell Death Ligand 1 Expression and Influences CD8+T Lymphocytes Cytotoxicity in an Orthotopic Hepatocellular Carcinoma Rat Model

  2024cites this paper
• Current application and future perspective of CRISPR/cas9 gene editing system mediated immune checkpoint for liver cancer treatment

  2024cites this paper
• The complex role of macrophages in pancreatic cancer tumor microenvironment: a review on cancer progression and potential therapeutic targets

  2024cites this paper
• Prognostic Role of Neutrophil to Lymphocyte Ratio at Diagnosis in Patients with Diffuse Large B-Cell Lymphoma.

  2024cites this paper
• Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population.

  2024cites this paper
• Tumor-infiltrating T-Lymphocyte immunity-related immune tolerance and anti–programmed cell death protein 1/ligand of programmed cell death protein 1 therapy for advanced hepatocellular carcinoma

  2024cites this paper
• Regulatory mechanisms of PD-1/PD-L1 in cancers

  2024cites this paper
• Nivolumab as Second-Line Therapy Improves Survival in Patients with Unresectable Hepatocellular Carcinoma

  2024cites this paper
• Immunotherapy and liver cancer research trends and the 100 most cited articles: A bibliometric analysis

  2024cites this paper
• Immunotherapy for hepatocellular carcinoma

  2024cites this paper
• Prognostic and therapeutic potential of imbalance between PD‐1+CD8 and ICOS+Treg cells in advanced HBV‐HCC

  2024cites this paper
• ANXA5: A Key Regulator of Immune Cell Infiltration in Hepatocellular Carcinoma

  2024cites this paper
• Emerging Prognostic Markers in Patients Undergoing Liver Resection for Hepatocellular Carcinoma: A Narrative Review

  2024cites this paper
• Case report: successful response to bevacizumab combined with erlotinib for a novel FH gene mutation hereditary leiomyoma and renal cell carcinoma

  2024cites this paper
• Prognostic biomarkers associated with immune checkpoint inhibitors in hepatocellular carcinoma

  2024cites this paper
• The TOPK inhibitor HI-TOPK-032 enhances CAR T-cell therapy of hepatocellular carcinoma by upregulating memory T cells.

  2024cites this paper
• Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic review

  2024cites this paper
• HBV DNA polymerase upregulates the transcription of PD-L1 and suppresses T cell activity in hepatocellular carcinoma

  2024cites this paper
• Role of immunotherapies and stem cell therapy in the management of liver cancer: A comprehensive review.

  2024cites this paper
• Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape.

  2024cites this paper
• The Adaptive Immune Response in Hepatitis B Virus-Associated Hepatocellular Carcinoma Is Characterized by Dysfunctional and Exhausted HBV-Specific T Cells

  2024influential citation
• The role of PD-1/PD-L1 signaling pathway in cancer pathogenesis and treatment: a systematic review

  2024cites this paper
• Advancements in locoregional therapy for advanced hepatocellular carcinoma: Emerging perspectives on combined treatment strategies.

  2024cites this paper
• Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study

  2024cites this paper
• Combined fibrinogen concentration and neutrophil-to-lymphocyte ratio, an integrative model of the inflammatory response and coagulation cascades, for predicting prognosis in patients with upper tract urothelial carcinoma

  2024cites this paper
• Prognostic significance of programmed cell death 1 expression on CD8+T cells in various cancers: a systematic review and meta-analysis

  2024cites this paper
• Potential targets and therapeutics for cancer stem cell-based therapy against drug resistance in hepatocellular carcinoma.

  2024cites this paper
• Epigenetic tuning of tumour-associated macrophages (TAMs): a potential approach in hepatocellular carcinoma (HCC) immunotherapy

  2024cites this paper
• Impact of glucose metabolism on PD-L1 expression in sorafenib-resistant hepatocellular carcinoma cells

  2024cites this paper
• Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data

  2023cites this paper
• Immune System and Hepatocellular Carcinoma (HCC): New Insights into HCC Progression

  2023cites this paper
• Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma

  2023cites this paper
• Adjuvant Atezolizumab-Bevacizumab after Resection or Ablation for Hepatocellular Carcinoma

  2023cites this paper
• Alteration of DNMT1/DNMT3A by eribulin elicits global DNA methylation changes with potential therapeutic implications for triple-negative breast cancer

  2023cites this paper
• Human circulating and tissue-resident memory CD8+ T cells

  2023cites this paper
• Decoding Immune Signature to Detect the Risk for Early-Stage HCC Recurrence

  2023cites this paper
• Potential Immunotherapy Targets for Liver-Directed Therapies, and the Current Scope of Immunotherapeutics for Liver-Related Malignancies

  2023cites this paper
• Therapeutic blocking of VEGF binding to neuropilin-2 diminishes PD-L1 expression to activate antitumor immunity in prostate cancer

  2023cites this paper
• Distribution characteristics and clinical significance of infiltrating T cells in the tumor microenvironment of pancreatic cancer

  2023cites this paper
• Impact of immune tolerance mechanisms on the efficacy of immunotherapy in primary and secondary liver cancers

  2023cites this paper
• A Systematic Review of Molecular Pathway Analysis of Drugs for Potential Use in Liver Cancer Treatment

  2023cites this paper
• The Roles of Epigenetic Regulation and the Tumor Microenvironment in the Mechanism of Resistance to Systemic Therapy in Hepatocellular Carcinoma

  2023cites this paper
• Cancer Immunology: Impact of Radioembolization of Heptocellular Carcinoma on Immune Response Modulation.

  2023cites this paper
• Correlation and efficacy of TACE combined with lenvatinib plus PD‐1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features

  2023cites this paper
• The CD8+ T cell exhaustion mechanisms in chronic hepatitis B infection and immunotherapeutic strategies: a systematic review

  2023cites this paper
• The interplay between noncoding RNAs and drug resistance in hepatocellular carcinoma: the big impact of little things

  2023cites this paper
• Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma

  2023cites this paper
• Antibody-based cancer immunotherapy by targeting regulatory T cells

  2023cites this paper
• Adjuvant ICIs Plus Targeted Therapies Reduce HCC Recurrence after Hepatectomy in Patients with High Risk of Recurrence

  2023cites this paper
• Immunotherapy for hepatocellular carcinoma: Recent advances and future targets.

  2023cites this paper
• Efficacy and Safety of TACE Combined with Regorafenib Plus PD-1 Inhibitor in the Treatment of Hepatocellular Carcinoma After Sorafenib Resistance

  2023cites this paper
• Radiation therapy in the era of immune treatment for hepatocellular carcinoma

  2023cites this paper
• Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma

  2023cites this paper
• Systemic Therapy for Advanced Hepatocellular Carcinoma: Current Stand and Perspectives

  2023cites this paper
• Evaluation of the possible association of PDCD-1 and LAG3 gene polymorphisms with hepatocellular carcinoma risk

  2023cites this paper
• The current status and future of PD-L1 in liver cancer

  2023cites this paper
• Identification of potential prognostic biomarkers among gene models for coiled-coil domain-containing family members in hepatocellular carcinoma elucidates their influence on the hypoxia pathway and immune microenvironment

  2023cites this paper
• LINC00887 regulates malignant progression and T-cell chemotaxis in clear cell renal cell carcinoma by activating CD70 via recruitment of SPI1.

  2023cites this paper
• Research Progress of PD-1/PD-L1 Signaling Pathway in Esophageal Squamous Cell Carcinoma

  2023cites this paper
• Combined Serum ALBUMIN with Neutrophil-to-Lymphocyte Ratio Predicts the Prognosis of Biliary Tract Cancer after Curative Resection

  2023cites this paper
• A multidisciplinary approach with immunotherapies for advanced hepatocellular carcinoma

  2023cites this paper
• FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2.

  2023cites this paper
• Phase I/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma

  2023cites this paper
• Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics

  2023cites this paper
• Innate Lymphoid Cells: Emerging Players in Pancreatic Disease

  2022cites this paper
• Correlation analysis for the alterations of intestinal ora and their metabolite in hepatocellular carcinoma patients

  2022cites this paper
• N6-Methyladenine-Related Signature for Immune Microenvironment and Response to Immunotherapy in Hepatocellular Carcinoma

  2022cites this paper
• The effects of immune checkpoint modulators on the clinical course of patients with resectable hepatocellular carcinoma

  2022cites this paper
• The Treatment Landscape of Advanced Hepatocellular Carcinoma

  2022cites this paper
• Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment

  2022cites this paper
• Role of ferroptosis-related molecular patterns in hepatocellular carcinoma microenvironment.

  2022cites this paper
• Prediction of programmed cell death protein 1 in hepatocellular carcinoma patients using radiomics analysis with radiofrequency-based ultrasound multifeature maps

  2022cites this paper
• WGCNA, LASSO and SVM Algorithm Revealed RAC1 Correlated M0 Macrophage and the Risk Score to Predict the Survival of Hepatocellular Carcinoma Patients

  2022cites this paper
• Rapidly Evolving Landscape and Future Horizons in Hepatocellular Carcinoma in the Era of Immuno-Oncology

  2022cites this paper
• Identification of GINS2 prognostic potential and involvement in immune cell infiltration in hepatocellular carcinoma

  2022cites this paper
• Immune checkpoint inhibitors in HCC: cellular, molecular and systemic data.

  2022cites this paper
• Potential of Compounds Originating from the Nature to Act in Hepatocellular Carcinoma Therapy by Targeting the Tumor Immunosuppressive Microenvironment: A Review

  2022cites this paper
• Prognostic impact of serum soluble PD-1 and ADV score for living donor liver transplantation in patients with previously untreated hepatocellular carcinoma

  2022cites this paper
• Sorafenib versus nivolumab after lenvatinib treatment failure in patients with advanced hepatocellular carcinoma

  2022cites this paper
• Interim efficacy and safety of PD-1 inhibitors in preventing recurrence of hepatocellular carcinoma after interventional therapy

  2022cites this paper